RxDoctor Payments DataLook up a doctor →

Harpaul Gill, MD

Neurology · Cypress, TXNPI 1023158409

Payments from drug & device makers

$1,188,333in general payments, 2019–2025

Across 1,628 payments — averaging $729.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$379K
  • E.r. Squibb & Sons, L.L.C.$336K
  • GSK$306K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$47K
  • Argenx US, Inc.$41K
  • Bristol Myers Squibb$26K
  • plus $52K from 54 others
$95,476in research payments, 2019–2025

Across 14 payments — averaging $6819.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$95K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)283$379,106
E.r. Squibb & Sons, L.L.C.10$335,639
GSK56$306,400
Otsuka Pharmaceutical Development & Commercialization, Inc.4$47,342
Argenx US, Inc.24$40,910
Bristol Myers Squibb6$26,301
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$20,997
Teva Pharmaceuticals USA, Inc.59$10,230
Novartis107$1,729
UCB, Inc.69$1,573
Acadia Pharmaceuticals Inc90$1,368
Neurocrine Biosciences, Inc.78$1,057
Biogen56$974
AstraZeneca(2 entities)42$955
SK Life Science, Inc.56$938
Lundbeck LLC48$870
Amneal Pharmaceuticals LLC48$761
Abbott40$724
Adamas Pharmaceuticals, Inc.26$607
Lilly USA, LLC32$543
Genentech USA, Inc.22$418
Sanofi22$413
Otsuka America Pharmaceutical, Inc.23$380
Octapharma USA, Inc.4$380
Biohaven Pharmaceutical Holding Company Ltd.48$372
TG Therapeutics, Inc.12$368
Astellas Pharma US Inc1$365
Neurelis, Inc.11$363
EMD Serono, Inc.19$336
Mallinckrodt Hospital Products Inc.12$321
Biohaven Pharmaceuticals, Inc.29$304
Jazz Pharmaceuticals Inc.12$285
Amgen(2 entities)16$283
Banner Life Sciences, LLC16$283
Supernus Pharmaceuticals, Inc.12$257
Catalyst Pharmaceuticals, Inc.8$212
Eisai Inc.9$197
Sumitomo Pharma America, Inc.16$190
Acorda Therapeutics, Inc9$189
Arbor Pharmaceuticals, Inc.11$184
Corium, LLC6$176
Impel Pharmaceuticals Inc.11$175
Johnson & Johnson(2 entities)6$159
Sunovion Pharmaceuticals Inc.18$146
Currax Pharmaceuticals LLC9$126
Merz Pharmaceuticals, LLC4$124
Avion Pharmaceuticals7$112
Bausch Health US, LLC4$107
Avanir Pharmaceuticals, Inc.7$106
Endo Pharmaceuticals Inc.6$104
Axsome Therapeutics, Inc.4$96
Upsher-smith Laboratories LLC6$92
GE HealthCare7$90
Vertical Pharmaceuticals, LLC5$86
Azurity Pharmaceuticals, Inc.5$84
Tanabe Pharma America, Inc.4$83
Grifols USA, LLC3$81
Medtronic(2 entities)4$77
Aquestive Therapeutics, Inc.5$77
Pfizer4$74

How this compares

$1,188,333 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas →

Medicare billing

Part B allowed, 2024
$650,388
Medicare patients
911
Services billed
6,025

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Cypress

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →